Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 3 1Phase 1/2 1

Status

Active not recruiting 4Terminated 1Completed 1

Sponsor Class

OTHER 3INDUSTRY 3

Study Type

Interventional 6

Sponsor

Cancer Type

Breast 6Gynecologic 1

Conditions

Breast Neoplasms 20Prostatic Neoplasms 7Triple Negative Breast Neoplasms 6Ovarian Neoplasms 4Neoplasm Metastasis 4Melanoma 3Lymphoma 3Lung Neoplasms 3Hematologic Neoplasms 3Endometrial Neoplasms 3Uterine Cervical Neoplasms 2Recurrence 2Neoplasms 2Multiple Myeloma 2Locally Advanced (Inoperable) or Metastatic Breast Cancer 2Leukemia 2Healthy Participants 2Disease Progression 2Carcinoma, Non-Small-Cell Lung 2Uterine Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumour 1Rectal Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1

Interventions

pembrolizumab 160Carboplatin 143Paclitaxel 125Cyclophosphamide 93130-nm albumin-bound paclitaxel 66Capecitabine 63Gemcitabine 54Doxorubicin 49Albumin-Bound Paclitaxel 45Taxes 42atezolizumab 40Cisplatin 37Nivolumab 34sacituzumab govitecan 32olaparib 32Epirubicin 32Docetaxel 28eribulin 27Specimen Handling 26Bevacizumab 26durvalumab 25camrelizumab 23Drug Therapy 22Biopsy 22Magnetic Resonance Spectroscopy 21toripalimab 18Radiotherapy 17spartalizumab 16Everolimus 15fludarabine 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Interventional × Triple Negative Breast Neoplasms × capivasertib × Clear all
NCT03742102 2026-04-24

BEGONIA

AstraZeneca

Phase 1/2 Active not recruiting
243 enrolled 13 charts
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03801369 2026-02-25

AMTEC IIT: Phase 2 Multiarm Study in TNBC

OHSU Knight Cancer Institute

Phase 2 Terminated
24 enrolled 16 charts
Breast

Triple Negative Breast Neoplasms

NCT02208375 2025-12-31

mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian

M.D. Anderson Cancer Center

Phase 1 Active not recruiting
159 enrolled
BreastGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT03997123 2025-12-22

CAPItello-290

AstraZeneca

Phase 3 Active not recruiting
923 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04556773 2025-12-17

DB-08

AstraZeneca

Phase 1 Active not recruiting
138 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02423603 2025-03-10

PAKT

Queen Mary University of London

Phase 2 Completed
71 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡